{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:19:28Z","timestamp":1790198368715,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508105"],"award-info":[{"award-number":["2023YFC2508105"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ40970"],"award-info":[{"award-number":["2021JJ40970"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373484"],"award-info":[{"award-number":["82373484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003362"],"award-info":[{"award-number":["82003362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82221002"],"award-info":[{"award-number":["82221002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130090"],"award-info":[{"award-number":["82130090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073447"],"award-info":[{"award-number":["82073447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003354"],"award-info":[{"award-number":["82003354"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaad.2025.06.019","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:44:58Z","timestamp":1749696298000},"page":"1000-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study"],"prefix":"10.1016","volume":"93","author":[{"given":"Junchen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingge","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.jaad.2025.06.019_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2025.06.019_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10275","key":"10.1016\/j.jaad.2025.06.019_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.019_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: from pathogenesis to targeted therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.019_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.019_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.019_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.019_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.06.019_bib9","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9625","key":"10.1016\/j.jaad.2025.06.019_bib10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.019_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.06.019_bib12","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.06.019_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.019_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.06.019_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/09546634.2014.880396","article-title":"Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper","volume":"26","author":"Girolomoni","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2025.06.019_bib16","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1111\/jdv.19652","article-title":"An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis","volume":"38","author":"Eyerich","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2025.06.019_bib17","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.06.019_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.06.019_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2025.06.019_bib20","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s13555-024-01229-6","article-title":"Comparison of drug-free remission after the end of phase III trials of three different anti-IL-23 inhibitors in psoriasis","volume":"14","author":"Hsieh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jaad.2025.06.019_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:37:02Z","timestamp":1778675822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225022960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0190962225022960"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}